奥浦迈: 奥浦迈：2025年半年度募集资金存放与实际使用情况的专项报告

Key Points - The report details the fundraising and usage of funds by Shanghai Aopumai Biotechnology Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations [1][2] - The total amount raised from the initial public offering (IPO) was approximately RMB 1.644 billion, with a net amount of RMB 1.637 billion after deducting issuance costs [1] - As of June 30, 2025, the company had spent RMB 318.4048 million on fundraising projects and had a remaining balance of RMB 151.2954 million in the fundraising account [1][2] Fundraising Overview - The actual amount raised was RMB 1,643,705,576.40, with a net amount of RMB 1,637,000,000 after fees [1] - The company utilized RMB 318.4048 million for project expenditures and invested RMB 546 million in financial products [1] - The company generated a net interest income of RMB 48.6477 million from the funds [1] Fund Usage and Management - The company has established a dedicated account for fundraising, with a balance of RMB 151.2954 million as of June 30, 2025 [1][2] - The company has permanently supplemented working capital with surplus funds amounting to RMB 192.8819 million [1] - The company has implemented a cash management strategy for idle funds, allowing for investment in high-security, liquid financial products [2][3] Project Status - The company has completed the fundraising projects "Aopumai CDMO Biopharmaceutical Commercialization Production Platform" and "Aopumai Cell Culture R&D Center," with surplus funds permanently allocated to working capital [1][2] - There were no changes to the fundraising project usage during the reporting period [4] Compliance and Reporting - The company has adhered to the regulations regarding fundraising management and disclosure, ensuring timely and accurate reporting of fundraising activities [4] - There were no violations in the management and disclosure of fundraising [4]